demyelinating

Stemazole is a novel small molecule human stem progenitor cell proliferation activator that promotes the survival of human embryonic stem cells and maintains stemness, and promotes the survival of oligodendrocyte precursor cells in vitro. Stemazole significantly increased cell survival and clone formation in a dose-dependent manner, reduced apoptosis, and promoted recovery of motor dysfunction and myelin repair. Stemazole can be used as a therapeutic agent in demyelinating disorders, promoting OPC survival in vitro and regeneration in vivo.

ARN-6039, an orally available inverse agonist of RORγ, targets Autoimmune Neuroinflammatory Demyelinating Disease. Its efficacy was demonstrated in a RORγ-activated IL-17A Prom LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 release from CD4+T cell assays (220 nM).

CAQK peptide specifically binds to injured mouse brain tissue and targets demyelinating areas without affecting healthy tissue. It interacts with a proteoglycan complex that is upregulated in brain injuries, making it useful for drug delivery applications. Additionally, CAQK peptide can penetrate the blood-brain barrier [1] [2].

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)), is a truncated peptide derived from the human Myelin Oligodendrocyte Glycoprotein (MOG).

PLP (180-199), an active biological peptide comprising amino acids 180-199 of myelin proteolipid protein (PLP)—the predominant myelin protein in the central nervous system (CNS)—is utilized in research focused on multiple sclerosis (MS), a chronic inflammatory demyelinating condition of the CNS.